Good news! Cancer is history (soon)!
"An mRNA vaccine has shown promise in four adults with the brain cancer glioblastoma, who had relapsed after previous treatment. The vaccine quickly triggered a strong immune response and all four people survived several months longer than expected. The results echo similarly positive outcomes in a study of 10 pet dogs who had been treated with the vaccine for terminal brain cancer. The ultimate goal, say the researchers, is to treat children, for whom brain cancer is the leading cause of cancer-related death."
From the highlights and abstract:
"Highlights
• RNA-LPAs mimic dangerous emboli for lymphoreticular entrapment and systemic immunity
• Systemic immunity resets both the peripheral and intratumoral milieu via IFNAR1/RIG-I
• RNA-LPAs are safe and effective tumor re-modulators in canines with spontaneous gliomas
• RNA-LPAs reprogram the TME and elicit adaptive immunity in human GBM patients
Summary
Cancer immunotherapy remains limited by poor antigenicity and a regulatory tumor microenvironment (TME). Here, we create “onion-like” multi-lamellar RNA lipid particle aggregates (LPAs) to substantially enhance the payload packaging and immunogenicity of tumor mRNA antigens. Unlike current mRNA vaccine designs that rely on payload packaging into nanoparticle cores for Toll-like receptor engagement in immune cells, systemically administered RNA-LPAs activate RIG-I in stromal cells, eliciting massive cytokine/chemokine response and dendritic cell/lymphocyte trafficking that provokes cancer immunogenicity and mediates rejection of both early- and late-stage murine tumor models. In client-owned canines with terminal gliomas, RNA-LPAs improved survivorship and reprogrammed the TME, which became “hot” within days of a single infusion. In a first-in-human trial, RNA-LPAs elicited rapid cytokine/chemokine release, immune activation/trafficking, tissue-confirmed pseudoprogression, and glioma-specific immune responses in glioblastoma patients. These data support RNA-LPAs as a new technology that simultaneously reprograms the TME while eliciting rapid and enduring cancer immunotherapy."
RNA aggregates harness the danger response for potent cancer immunotherapy (no public access)
Graphical abstract
No comments:
Post a Comment